RCEL vs. FNA, BFLY, ESTA, EYE, BBNX, EMBC, BVS, AXGN, CBLL, and AVNS
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include Paragon 28 (FNA), Butterfly Network (BFLY), Establishment Labs (ESTA), National Vision (EYE), Beta Bionics (BBNX), Embecta (EMBC), Bioventus (BVS), AxoGen (AXGN), CeriBell (CBLL), and Avanos Medical (AVNS). These companies are all part of the "medical equipment" industry.
AVITA Medical vs.
AVITA Medical (NASDAQ:RCEL) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
AVITA Medical presently has a consensus target price of $17.25, indicating a potential upside of 76.92%. Paragon 28 has a consensus target price of $14.60, indicating a potential upside of 12.18%. Given AVITA Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe AVITA Medical is more favorable than Paragon 28.
27.7% of AVITA Medical shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 1.8% of AVITA Medical shares are held by company insiders. Comparatively, 15.3% of Paragon 28 shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Paragon 28 has a net margin of -25.31% compared to AVITA Medical's net margin of -96.26%. Paragon 28's return on equity of -37.90% beat AVITA Medical's return on equity.
In the previous week, AVITA Medical had 13 more articles in the media than Paragon 28. MarketBeat recorded 13 mentions for AVITA Medical and 0 mentions for Paragon 28. AVITA Medical's average media sentiment score of 0.46 beat Paragon 28's score of 0.00 indicating that AVITA Medical is being referred to more favorably in the media.
AVITA Medical received 45 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 76.09% of users gave Paragon 28 an outperform vote while only 69.57% of users gave AVITA Medical an outperform vote.
AVITA Medical has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.
Paragon 28 has higher revenue and earnings than AVITA Medical. Paragon 28 is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Paragon 28 beats AVITA Medical on 10 of the 17 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
This page (NASDAQ:RCEL) was last updated on 2/22/2025 by MarketBeat.com Staff
